Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint
Achilleas Floudas, … , Douglas J. Veale, Ursula Fearon
Achilleas Floudas, … , Douglas J. Veale, Ursula Fearon
Published November 5, 2020
Citation Information: JCI Insight. 2020;5(21):e139032. https://doi.org/10.1172/jci.insight.139032.
View: Text | PDF
Research Article Cell biology Metabolism

Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint

  • Text
  • PDF
Abstract

While autoantibodies are used in the diagnosis of rheumatoid arthritis (RA), the function of B cells in the inflamed joint remains elusive. Extensive flow cytometric characterization and SPICE algorithm analyses of single-cell synovial tissue from patients with RA revealed the accumulation of switched and double-negative memory programmed death-1 receptor–expressing (PD-1–expressing) B cells at the site of inflammation. Accumulation of memory B cells was mediated by CXCR3, evident by the observed increase in CXCR3-expressing synovial B cells compared with the periphery, differential regulation by key synovial cytokines, and restricted B cell invasion demonstrated in response to CXCR3 blockade. Notably, under 3% O2 hypoxic conditions that mimic the joint microenvironment, RA B cells maintained marked expression of MMP-9, TNF, and IL-6, with PD-1+ B cells demonstrating higher expression of CXCR3, CD80, CD86, IL-1β, and GM-CSF than their PD-1– counterparts. Finally, following functional analysis and flow cell sorting of RA PD-1+ versus PD-1– B cells, we demonstrate, using RNA-Seq and emerging fluorescence lifetime imaging microscopy of cellular NAD, a significant shift in metabolism of RA PD-1+ B cells toward glycolysis, associated with an increased transcriptional signature of key cytokines and chemokines that are strongly implicated in RA pathogenesis. Our data support the targeting of pathogenic PD-1+ B cells in RA as a focused, novel therapeutic option.

Authors

Achilleas Floudas, Nuno Neto, Viviana Marzaioli, Kieran Murray, Barry Moran, Michael G. Monaghan, Candice Low, Ronan H. Mullan, Navin Rao, Vinod Krishna, Sunil Nagpal, Douglas J. Veale, Ursula Fearon

×

Figure 2

Synovial tissue accumulation of DN and switched memory B cells in RA.

Options: View larger image (or click on image) Download as PowerPoint
Synovial tissue accumulation of DN and switched memory B cells in RA.
(A...
(A) Representative plots of CD19+CD20+ B cells for the expression of IgD and CD27 in the peripheral blood, SF, and synovial tissue (at least 5 independent experiments performed). (B) Average subpopulation distribution of peripheral blood HC and RA patient B cells and RA patient SF and synovial tissue B cells. (C) Frequency of the indicated B cell populations in the periphery (n = 20), SF (n = 12), and synovial tissue (n = 6) of RA patients. Data are presented as mean ± SEM. Each symbol represents an individual sample. Statistical analysis was performed by using 1-way ANOVA with Tukey’s multiple-comparisons test. **P < 0.01, ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts